Amicus Therapeutics (NASDAQ:FOLD) Earns “Hold” Rating from Needham & Company LLC

Amicus Therapeutics (NASDAQ:FOLD)‘s stock had its “hold” rating reiterated by investment analysts at Needham & Company LLC in a report released on Friday,Benzinga reports.

A number of other research firms have also recently issued reports on FOLD. The Goldman Sachs Group raised their price target on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Monday. Citigroup initiated coverage on Amicus Therapeutics in a research report on Wednesday. They set a “buy” rating and a $17.00 price target for the company. JPMorgan Chase & Co. raised their price objective on Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Finally, Wall Street Zen upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.36.

Amicus Therapeutics Stock Up 30.7%

Amicus Therapeutics stock traded up $3.35 during midday trading on Friday, reaching $14.24. The company’s stock had a trading volume of 117,020,766 shares, compared to its average volume of 4,748,287. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.99 and a quick ratio of 2.09. The stock has a market capitalization of $4.39 billion, a P/E ratio of -355.79 and a beta of 0.46. The stock’s 50-day simple moving average is $9.36 and its 200-day simple moving average is $7.77. Amicus Therapeutics has a 52-week low of $5.51 and a 52-week high of $14.36.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. The business had revenue of $169.06 million for the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The company’s revenue was up 19.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.10 earnings per share. On average, sell-side analysts expect that Amicus Therapeutics will post 0.15 EPS for the current year.

Insiders Place Their Bets

In other Amicus Therapeutics news, insider David Michael Clark sold 25,643 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $11.00, for a total value of $282,073.00. Following the transaction, the insider directly owned 271,332 shares of the company’s stock, valued at $2,984,652. This trade represents a 8.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jeff Castelli sold 76,158 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $10.16, for a total transaction of $773,765.28. Following the completion of the sale, the insider directly owned 439,318 shares of the company’s stock, valued at $4,463,470.88. This represents a 14.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 319,808 shares of company stock valued at $3,293,653 over the last ninety days. 2.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in FOLD. Vestal Point Capital LP boosted its holdings in shares of Amicus Therapeutics by 178.4% in the second quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock valued at $68,187,000 after acquiring an additional 7,625,000 shares during the period. Norges Bank purchased a new position in Amicus Therapeutics during the 2nd quarter worth $18,540,000. Assenagon Asset Management S.A. grew its position in Amicus Therapeutics by 641.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,533,854 shares of the biopharmaceutical company’s stock worth $20,249,000 after purchasing an additional 3,057,072 shares during the last quarter. Millennium Management LLC increased its stake in Amicus Therapeutics by 635.1% in the first quarter. Millennium Management LLC now owns 3,359,389 shares of the biopharmaceutical company’s stock valued at $27,413,000 after purchasing an additional 2,902,375 shares during the period. Finally, Redmile Group LLC boosted its stake in shares of Amicus Therapeutics by 35.1% during the first quarter. Redmile Group LLC now owns 9,533,669 shares of the biopharmaceutical company’s stock worth $77,795,000 after buying an additional 2,478,779 shares during the period.

Key Amicus Therapeutics News

Here are the key news stories impacting Amicus Therapeutics this week:

• Positive Sentiment: BioMarin agreed to acquire Amicus in an all-cash deal valuing the company at roughly $4.8 billion (about $14.50 per share). BioMarin highlighted that the deal brings marketed products (Galafold and Pombiliti + Opfolda), recent product revenue (~$599M last four quarters), and expected near-term accretion to non‑GAAP EPS, which supports a near-term valuation floor for FOLD shares and provides cash certainty for holders. BioMarin to Acquire Amicus Therapeutics for $4.8 Billion
• Neutral Sentiment: Trading in FOLD was temporarily halted ahead of the announcement (standard procedure for material M&A news), which concentrated volume and volatility once the halt lifted. (No article link)
• Neutral Sentiment: Citigroup initiated coverage on Amicus (adds analyst attention and liquidity), which can influence sentiment and provide updated investor models but is not a direct fundamental change. Citigroup Begins Coverage on Amicus Therapeutics
• Negative Sentiment: An investor-rights law firm (Halper Sadeh LLC) has launched an investigation into whether the $14.50-per-share sale is fair to Amicus shareholders, which could lead to litigation or delay and potentially put pressure on deal timing or terms. FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
• Negative Sentiment: Recent insider sales (including the CEO and another insider selling in mid‑December) may raise questions for some investors about timing of dispositions ahead of the deal—worth monitoring for governance/ optics issues. Insider Filing (SEC)

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.